Akebia Ther
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and … Read more
Akebia Ther (AKBA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.955x
Based on the latest financial reports, Akebia Ther (AKBA) has a cash flow conversion efficiency ratio of 0.955x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($31.13 Million) by net assets ($32.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Akebia Ther - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Akebia Ther's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Akebia Ther Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Akebia Ther ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sella Capital Real Estate Ltd
PINK:STCPF
|
0.021x |
|
Chatham Lodging Trust REIT
NYSE:CLDT
|
0.016x |
|
Hellenic Exchanges - Athens Stock Exchange SA
PINK:HEHSF
|
0.162x |
|
Xiamen Solex High-Tech Industries Co Ltd
SHG:603992
|
0.021x |
|
Arafura Resources Limited
DU:REB
|
-0.131x |
|
Zhejiang Kan Specialities Material Co Ltd
SHE:002012
|
-0.005x |
|
Iteos Therapeutics Inc
NASDAQ:ITOS
|
-0.086x |
|
Hynar Water Group Co. Ltd.
SHE:300961
|
N/A |
Annual Cash Flow Conversion Efficiency for Akebia Ther (2012–2025)
The table below shows the annual cash flow conversion efficiency of Akebia Ther from 2012 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $32.61 Million | $67.99 Million | 2.085x | +152.22% |
| 2024-12-31 | $-49.19 Million | $-40.66 Million | 0.827x | +8.12% |
| 2023-12-31 | $-30.58 Million | $-23.38 Million | 0.765x | +105.47% |
| 2022-12-31 | $5.23 Million | $-73.15 Million | -13.987x | -309.22% |
| 2021-12-31 | $74.01 Million | $-252.97 Million | -3.418x | -666.73% |
| 2020-12-31 | $247.62 Million | $-110.39 Million | -0.446x | +31.64% |
| 2019-12-31 | $394.76 Million | $-257.44 Million | -0.652x | -325.38% |
| 2018-12-31 | $635.93 Million | $-97.49 Million | -0.153x | +67.42% |
| 2017-12-31 | $119.33 Million | $-56.16 Million | -0.471x | -155.36% |
| 2016-12-31 | $68.12 Million | $57.91 Million | 0.850x | +312.48% |
| 2015-12-31 | $131.00 Million | $-52.41 Million | -0.400x | -51.50% |
| 2014-12-31 | $104.08 Million | $-27.48 Million | -0.264x | +28.33% |
| 2013-12-31 | $30.76 Million | $-11.33 Million | -0.368x | -113.69% |
| 2012-12-31 | $-2.68 Million | $-7.21 Million | 2.691x | -- |